Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Deciphera Pharmaceuticals reports robust Q4 performance and eyes market expansion

Deciphera Pharmaceuticals delivered strong financial results and outlined strategic priorities for future growth.
The company's focus on ctDNA analysis, market expansion, and potential label expansions position them well for continued success.
While facing uncertainties in guideline updates and market competition, Deciphera Pharmaceuticals remains optimistic about growth opportunities.

Deciphera Pharmaceuticals excels in Q1 2023, eyes international expansion

Deciphera Pharmaceuticals demonstrates strong financial performance and strategic achievements in Q1 2023, positioning the company for continued growth and market success.
While facing challenges from market dynamics and competition, the company's focus on international expansion, new drug development, and commercialization efforts presents promising opportunities.
By leveraging strengths in reimbursement ratings, clinical significance of key drugs, and pre-commercial activities, Deciphera is poised to capitalize on market opportunities and drive future growth.

Deciphera Pharmaceuticals excels in Q2, eyes international growth and innovation

Deciphera Pharmaceuticals delivered a standout performance in Q2 2023, driven by QINLOCK's robust revenue generation and international expansion.
While facing challenges such as high operating expenses and clinical trial complexities, the company remains focused on patient outcomes and program advancements.
Opportunities lie in continued revenue growth, clinical program progress, and leadership transitions, positioning Deciphera for future success and innovation.

Deciphera Pharmaceuticals excels in Q3 with record sales and innovative pipeline

Deciphera Pharmaceuticals shows strong financial and clinical performance in Q3 2023.
Balancing successful study outcomes with potential regulatory challenges and patient dynamics.
Company poised for significant revenue growth and market expansion with innovative products.
Continued focus on commercial success and pipeline advancement to drive future growth.

Deciphera Pharmaceuticals reports robust Q4 performance and eyes global expansion

Deciphera Pharmaceuticals showcased strong financial performance, clinical advancements, and strategic plans for growth in Q4 2023, positioning the company for continued success.
While facing challenges in market differentiation and operational execution, the company has opportunities for market expansion, record sales, and clinical development milestones in 2024.
Overall, Deciphera Pharmaceuticals' focus on QINLOCK sales, vimseltinib development, and international expansion underscores a comprehensive growth strategy and potential for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib, a colony stimulating factor 1 receptor (CSF1R), for the treatment of patients with tenosynovial giant cell tumor (TGCT), which is under development by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly-owned subsidiary of.

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois,.

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.60 per share a year ago.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd. Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

OSAKA, Japan , April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L.

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

NEW YORK , April 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) , relating to its proposed merger with ONO Pharmaceutical Co., Ltd.

INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion.  Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.

ONO to buy Deciphera Pharmaceuticals at a huge premium

Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.

Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?

MILWAUKEE , April 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with ONO. Click here to learn how to join the https://www.ademilaw.com/case/deciphera-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.

Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.

Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion

Deciphera Pharmaceuticals is being bought by Japan's ONO Pharmaceutical in a deal valued at $2.4 billion.

Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to ONO Pharmaceutical Co., Ltd. for $25.60 per share in cash is fair to Deciphera shareholders. Halper Sadeh encourages Deciphera shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation co.

DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders

Deciphera Pharmaceuticals Inc. DCPH, +3.31% said Monday it has agreed to be acquired by Japan's Ono Pharmaceutical Co. Ltd 4528, +1.34% in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono will pay $25.60 per Deciphera share through a tender offer after which it will merge the Waltham, Mass.

Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion

Deciphera Pharmaceuticals said on Monday Japan's ONO Pharmaceutical Co will acquire the company for $2.4 billion in cash.

Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of.

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Deciphera Pharmaceuticals, Inc.  (NASDAQ: DCPH) on behalf of the company's shareholders.  The investigation seeks to determine whether Deciphera Pharmaceuticals, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET. A live webcast of the fireside chat will be available on the “Events and Presentatio.

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?

The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA Leerink Partners Global Biopharma Conferen.

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Deciphera Pharmaceuticals Stock (DCPH)